Q2 2025

Filed Aug 12, 2025 · 10-Q · 43 days after period end · 0001730463-25-000067

Q2 2025 · 10-Q

Revenue

$20.92M

— vs Q2 2024

Net Income

-$47.92M

N/M vs Q2 2024

EPS Diluted

-$0.18

N/M vs Q2 2024

Operating Income-$61,217,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$20.92M	$0.00	—	—
Net Income	-$47.92M	-$58.27M	-$45.55M	-$42.06M
EPS Diluted	-$0.18	-$0.22	-$0.26	-$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR